Innate Pharma S.A.
Innate Pharma S.A.（IPHA）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
ipha · 股价预测 · 6 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 6 位华尔街分析师
Buy
6 位分析师
共识
评级分布
12 个月目标价
High
$5.00
Consensus
$3.50
+97.7% upside
Low
$2.00
Median: $3.5 · Last Close: $1.77
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$3.50
97.7% upside
High Target
$5
182.5%
Low Target
$2
13.0%
Current Price
$1.77
as of today
Based on analyst price targets, the IPHA stock price prediction for the next 12 months ranges from $2 to $5. The consensus IPHA price forecast of $3.50 implies 97.7% upside from the current price of $1.77.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.75 | ↓ 1.40% |
1-day model range: $1.7–$1.79. Peak: $1.79 (-1.40%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IPHA · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-29 | BTIG | Maintains | Buy→Buy |
| 2025-10-29 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2025-09-18 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-04-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Innate Pharma S.A. (IPHA) stock. Of the recent 34 rating actions, 3 were upgrades and 3 were downgrades. 6 analysts currently cover IPHA.
分析师推荐趋势
IPHA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$31M
↓ 24.1% YoY
Revenue Next Year
$64M
↑ 106.8% YoY
EPS This Year
$-0.25
EPS Next Year
$0.04
↓ 117.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast IPHA EPS of $-0.25 for the current fiscal year, based on estimates from 2 analysts. The IPHA revenue forecast is $31M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
IPHA 股价预测由两类独立数据源支撑：来自 6 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。IPHA 的共识目标价为 $3.50（+97.7% 上行空间），分析师共识为 Buy。
IPHA 的短期预测（明日）为 $1.75（-1.40%）。 IPHA 对 2027 年的股价预测均值为 $1。 IPHA 对 2030 年的预测区间为 $0–$1。
Innate Pharma S.A. 在 NASDAQ 上市，代码 IPHA。IPHA 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。
常见问题
IPHA 预测 · 8 个问题根据 6 位华尔街分析师，IPHA 的 12 个月平均目标价为 $3.50，最高 $5.00、最低 $2.00。若有图表，中位目标价可在上方查看。相对当前价 $1.77，隐含约 +97.7% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.